Spontaneous pregnancy toxaemia (ketosis) in sheep and the role of insulin.
214 ewes suffering from pregnancy toxaemia (ketosis) were examined. Clinical signs during onset and course of disease and laboratory findings were compared between animals that survived and those which died. In the latter the onset of ketosis was earlier in pregnancy (day 143 +/- 7 vs. day 146 +/- 8) and duration of the disease was shorter (10 +/- 13 vs. 14 +/- 9 days). The animals that died showed more severe clinical signs and higher values of 3-hydroxy-butyrate (4.3 +/- 3.6 vs. 3.5 +/- 2.6 mmol/l) and cortisol (72 +/- 98 vs. 52 +/- 80 mmol/l) as well as lower values of insulin (37 + 12 vs. 3.5 + 2.6 mmol/l) and potassium (4.1 + 1.0 vs. 4.4 + 1.0 mmol/1) at onset of the disease than those which survived (all of differences with P < 0.05). Glucose levels did not differ between groups. Treated animals with glucose plus fructose infusions (n = 56) or with oral application of glucose precursors plus electrolytes (n = 126) had survival rates of 53.6% and 62.7%, respectively. Oral treatment with glucose precursors plus electrolytes and an additional subcutaneous insulin treatment (n = 15) led to an enhanced survival rate of 86.7% (P < 0.05). Low insulin levels in ketotic pregnant sheep and the therapeutic effect of insulin treatment support the hypothesis that insulin plays a causative role in the pathogenesis of ovine ketosis.
Klinik für kleine Klauentiere, Tierärztliche Hochschule Hannover, Germany.
P
P
Henze
K
K
Bickhardt
H
H
Fuhrmann
H P
HP
Sallmann
D020155:3-Hydroxybutyric Acid; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D005260:Female; D006885:Hydroxybutyrates / Q000097:blood; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood / Q000627:therapeutic use*; D007662:Ketosis / Q000209:etiology / Q000628:therapy / Q000662:veterinary*; D011225:Pre-Eclampsia / Q000209:etiology / Q000628:therapy / Q000662:veterinary*; D011247:Pregnancy; D012756:Sheep; D012757:Sheep Diseases / Q000209:etiology / Q000628:therapy*
D001786:Blood Glucose; D006885:Hydroxybutyrates; D007004:Hypoglycemic Agents; D007328:Insulin; D020155:3-Hydroxybutyric Acid